Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $91.83

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $91.8333.

A number of analysts recently weighed in on TARS shares. Barclays began coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $100.00 price objective for the company. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Guggenheim increased their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th.

Tarsus Pharmaceuticals Trading Down 3.4%

Shares of NASDAQ TARS opened at $64.51 on Thursday. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The firm has a market cap of $2.75 billion, a PE ratio of -39.82 and a beta of 0.55. The business has a fifty day simple moving average of $69.12 and a two-hundred day simple moving average of $70.30. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published narrower FY‑2026 and quarterly EPS losses (they now model materially smaller losses vs. consensus), supporting a more constructive recovery thesis for the name. Lifesci Capital report
• Neutral Sentiment: Street consensus remains mixed-to-favorable (average “Moderate Buy”); Lifesci’s bullish view improves outlook but is not yet unanimous across analysts. Analyst consensus
• Neutral Sentiment: Last reported quarter: slight EPS miss (reported ($0.20) vs. ($0.19) est.) but revenue beat — fundamentals are mixed and future price action depends on clinical/launch catalysts and execution. Quarterly results
• Neutral Sentiment: High institutional ownership (~90%) concentrates the float — can stabilize but also amplify moves if large holders or insiders trade. Ownership details
• Negative Sentiment: Clustered insider selling across Mar 16–19: CEO Bobak Azamian sold multiple tranches (totaling ~34,600 shares across Mar 17–19 at ~$67–$69), Director William J. Link sold 12,500 shares, and several other senior officers trimmed positions — large, concentrated insider sales often create short‑term downward pressure and raise questions about timing/intent. Insider sales roundup
• Negative Sentiment: Multiple SEC Form 4s disclose the CEO’s and other officers’ sales (detailed fills and dates are available in the filings), which investors may view as meaningful liquidity events rather than routine small trades. SEC Form 4 (example)

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 4,174 shares of the company’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the sale, the insider directly owned 35,028 shares in the company, valued at $2,346,876. This represents a 10.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, General Counsel Bryan Wahl sold 4,231 shares of the firm’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $283,477.00. Following the sale, the general counsel directly owned 63,959 shares in the company, valued at approximately $4,285,253. The trade was a 6.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 85,391 shares of company stock worth $5,927,095. 8.97% of the stock is currently owned by company insiders.

Institutional Trading of Tarsus Pharmaceuticals

Hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Tarsus Pharmaceuticals by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after buying an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after acquiring an additional 1,394 shares during the last quarter. Jane Street Group LLC lifted its position in Tarsus Pharmaceuticals by 105.8% during the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after acquiring an additional 190,000 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in Tarsus Pharmaceuticals by 15.9% in the second quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock valued at $420,000 after acquiring an additional 1,418 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Tarsus Pharmaceuticals by 8.0% in the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock valued at $37,859,000 after acquiring an additional 68,986 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.